Fast Five Quiz: HR-Positive/HER2-Negative Breast Cancer

Winston W. Tan, MD; Stefania Morganti, MD


June 28, 2023

Hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER-) is the most common breast cancer subtype.

Endocrine therapy represents the cornerstone of treatment of this tumor subtype, both in the early-stage and in the metastatic setting. All patients with early-stage HR+/HER2- breast cancer are candidates to receive adjuvant endocrine therapy with tamoxifen or aromatase inhibitors. Patients with metastatic HR+/HER2- breast cancer are instead treated with sequence of endocrine-based regimens until the tumor is considered endocrine-sensitive and derive clinical benefit. Endocrine-based regimen typically consist in an endocrine agent (eg, an aromatase inhibitor, a SERD or a SERM) as monotherapy or combined with a targeted agent, such as CDK4/6 inhibitors (eg, palbociclib , abemaciclib, ribociclib), mTOR inhibitors (eg, everolimus), or PIK3CA inhibitors (eg, alpelisib). With the availability of new data and novel therapies, the clinical practice challenge becomes how best to define the optimal treatment sequence to maximize clinical benefit.

What do you know about HR+/HER2- breast cancer? Test your knowledge with this quick quiz.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.